. . . and this educational activity is intended for healthcare providers and is supported by grants from AstraZeneca, Bayer, Chiesi, and NovoNordisk.
2) Let's start with a case. Meet Masika: 66 year old non-frail woman with #T2D x 15 yrs , MI 2 yrs ago, hypertension, no heart failure, otherwise well. On metformin, #GLP1-RA, #SGLT2i, sulfonylurea. BMI 30 kg/m2, A1c 7.9%, eGFR 66, normal ACR, LDL at target.
3) What is the target A1c that you would discuss with Masika?
a) ≤6.5% (48 mmol/mol)
b) ≤7.0% (53 mmol/mol)
c) 7.1-8.0% (54-64 mmol/mol)
d) ≥8.1% (65 mmol/mol)
4) Consistent with guidelines from around the world, it would be appropriate to target A1c ≤7% (choice b), given that she is non-frail. @DiabetesCanada
5) … and the reduction in microvascular and macrovascular complications that she can derive from the lower A1c
6) What is the next appropriate antihyperglycemic therapy to offer her to lower the glucose levels?
a)Basal insulin
b)Premixed insulin
c)Bolus insulin
d)Fixed ratio combination of GLP-1RA + basal insulin
9) After #GLP-1RA, add basal insulin or transition to fixed ratio combo of GLP-1RA + basal insulin. Consistent with consensus algorithm from @AmDiabetesAssn@EASDnews. 4T study (DOI: 10.1056/NEJMoa075392) . . .
10) . . . showed that basal start had less hypoglycemia and weight gain compared to other insulin regimens
11) Despite advances in insulin, initiation still is often delayed by many yrs. Why?
a) System-related factors (low access, lack of time)
b) Provider factors (lack of time/experience, inertia)
c) Patient factors (fear of insulin, stigma, fear of wgt gain)
d) All of the above
12) Correct answer: D – all of the above.
13) Delaying advancement of therapy by 1 yr is associated with the loss of ~13,390 life-yrs and increased cost of USD 7.3 billion (1-yr time horizon, see DOI: 10.1007/s12325-019-01199-8). What can we do to address this inertia?
14) Educate ourselves – as you are doing now. Know Who, What and How of insulin use in type 2 diabetes. Here’s the “Who”.
15) Here’s the “what”. All available insulins can be classified as Bolus (mealtime), Basal or Premixed. Here is a VERY handy insulin prescription tool from @DiabetesCanada . . .
16) . . . that has made one of the hard parts (prescription) easier. Page 2 has the insulin start & titration “cheat sheet” diabetes.ca/DiabetesCanada…
17) For the “How”, we need to self-reflect. The negative perception of insulin often comes from us. Insulin = “replacement” therapy. It is not punishment or threat. It is not the end of the road.
18) Ask and listen to patient’s concerns. Show the insulin delivery systems. Consider a “dry injection” in office. This will go far to allay fears.
19) Do not get hung up on the starting dose of insulin. It will be wrong! It is ALL ABOUT THE TITRATION. If you are not going to titrate, do not bother starting. Usual basal starting dose is 10 units or 0.2 units/kg. #Titration is the key!
20) Who should be the primary person(s) to titrate the insulin?
22) Welcome back! Let's wrap this up. THANK YOU for following us for Twitter-delivered CE/#CME. Credits available also in Canada, GB, and EU--all FREE. I am @AliceYYCheng and I left you with a question yesterday!
23) Self-titration by person w/#diabetes is as effective (or more) than HCP-led. If glucose testing is available, teach self-titration of basal insulin using simple algorithm. In Canada, we increase by 1 unit daily until fasting glucose target reached guidelines.diabetes.ca/docs/cpg/Appen…
24) Pro tip: when teaching self-titration, give context – starting at low dose, will likely need 50-60 units to reach target. This gives context so person more likely to keep titrating.
25) Successful titration requires ongoing support from interprofessional providers - always involve #diabetes education team (nurse, #dietitian, pharmacist etc)
26) Inadequate titration continues to be a barrier even when people are started on insulin as evidenced by the markedly reduced proportion of people w/#T2D achieving A1c <7% on insulin. More work needs to be done!
27) Final thoughts: Words matter (frame insulin properly from diagnosis). Basal insulin is preferred start in #T2D. The starting dose will always be wrong. Titration is the key. Empower the person living w/#diabetes to self-titrate.
Welcome to our final Goggledocs tweetorial from this #EASD2021 takeover!
Over the last few days we have discussed all things cardio-reno-metabolic including SGLT2s, GLP1s, dual agonists, triple agonists….but not mentioned much about type 1 diabetes…
So today we are going to end on a cardiometabolic focused look at Type 1 Diabetes with data from #EASD2021 interwoven in... stay tuned!
Today I will be going through some of the preliminary data from the ReTune Study
📍Twin Cycle Hypothesis (R. Tayor 2008) of #type2diabetes
📍Once an individual' subcutaneous fat reserves are full
▶️ Fat is stored in the liver
▶️ Liver derived VLDL in turn, among other things, ⤴️ pancreatic fat
▶️⤴️pancreatic fat leads onto ⤵️ insulin secretion to food
This accredited educational program is intended for healthcare providers only, and is supported by grants from AstraZeneca, Bayer, Chiesi, and NovoNordisk. Follow this thread for a link to credit. CE/#CME credit for #physicians, #nurses, #pharmacists in US, Canada, GB, EU.
STEP this way for the last of our tweetorials covering #ESCCongress@escardio Looking at a trial of intensive blood pressure control in older adults with hypertension
First...step aside to a different STEP trial – Semaglutide in Obesity – our last tweetorial on this was very popular – have a look!